Gabapentin Capsule
Product Images NDC 81279-126

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 81279-126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pangea Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Equation (Equation)

Equation (Equation)
A mathematical formula showing creatinine clearance (CLCr) calculation based on age, weight, and serum creatinine. The formula includes an adjustment factor of 0.85 for female patients. This text appears to be part of clinical or dosing information related to Gabapentin capsules 200 mg by Pangea Pharmaceuticals.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A line graph showing weekly mean pain scores over eight weeks for two groups in a study: placebo and Gabapentin 3600 mg/day. The horizontal axis represents weeks, and the vertical axis measures mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin scores decreasing notably compared to placebo.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
Line graph showing weekly mean pain scores over 7 weeks in a study population. It compares Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day groups during a 3-week dose titration period followed by a 4-week fixed dose period. Mean pain scores decrease more in the Gabapentin groups versus placebo over time.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A bar chart titled 'Proportion of Responders (patients with 250% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) treatment groups in two studies. The y-axis shows the percentage of responders from 0% to 100%. Study 1 shows 12% for PBO and 29% for GBP 3600 mg with statistical significance noted. Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, with significant differences indicated.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A scatter plot showing responder rate differences in percentage for patients receiving Gabapentin versus placebo by daily dose (mg) across three studies (Study a, Study b, Study c). The horizontal axis represents daily dose in mg ranging from 600 to 1800, and the vertical axis shows percentage difference from 2% to 22%. Different shading represents different studies with corresponding responder rates marked at various doses.*
FDA Label Image

Gabapentine Capsule 200mg (Gabapentin 200mg)

Gabapentine Capsule 200mg (Gabapentin 200mg)
Label for Gabapentin Capsules, USP, 200 mg strength, oral capsules. The label specifies storing conditions from 20°C to 25°C with permitted excursions, child-resistant packaging, and dispensing instructions. The product is manufactured for Pangea Pharmaceuticals, LLC. The label also includes a barcode, medication guide URL, and a batch coding area. The package contains 60 capsules and is labeled Rx only.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of gabapentin. The diagram shows a cyclohexane ring bonded to an amine group (CH2NH2) and a carboxylic acid group (CH2CO2H), depicting the core molecular structure of gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.